摘要:
Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
摘要:
Methods, systems and apparatuses for dynamic spectrum access by both primary users (PUs) and secondary users (SUs) are disclosed. In one embodiment, a method for communicating over a channel may include obtaining, at a secondary transmitter, first and second signals intended for a primary receiver and secondary receivers, respectively; generating, at the secondary transmitter, an assist signal based, at least in part, on the obtained first signal; generating, at the secondary transmitter, a data signal based, at least in part, on the obtained second signal; determining, at the secondary transmitter, a power split ratio between the data signal and the assist signal based, at least in part, on any of a power and a signal-to-noise ratio of the first signal; and generating, at the secondary transmitter, a third signal comprising (i) the data signal and (ii) the assist signal in accordance with power split ratio.
摘要:
A system and method to generate and maintain controlled growth DAG are described. The controlled growth DAG conveys information about objects captured by a capture system.
摘要:
A HRPD network access authentication method based on CAVE algorithm is provided. An AT (Access Terminal) generates a random number “RAND” necessary for a calculation of an AUTH1 by using a “Random text” included in the CHAP Challenge message. A UIM (User Identity Module) card works out the AUTH1 by using the random number “RAND” and an SSD_A (Shared Secret Data A) in the UIM card. The AT carries the AUTH1 in a Result field of the CHAP Response message. An AN-AAA (Access Network-Authentication, Authorization, and Accounting) generates the random number “RAND” necessary for the calculation of an AUTH2 by using a “Random text” included in a Radius Access Request message. The AN-AAA works out the AUTH2 by using the random number “RAND”. The two results AUTH1 and AUTH2 are compared. If the results are the same, the authentication on the AT passes. Otherwise, AT access is rejected.
摘要:
Disclosed are compounds of formula (I): wherein the variables R1, R2, R3 and Z are described herein, which are useful as inhibitors of the kinase activity of the IκB kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.
摘要:
The present invention provides a process for producing copper nanoparticles, comprising steps of: a) reacting an aqueous solution containing a reductant with an aqueous solution of a copper salt while stirring for 1-8 min, wherein the reductant being one or more selected from a group consisting of hydrazine hydrate, sodium borohydride and sodium hypophosphite; b) adding an apolar organic solution containing the extracting agent and continuing the stirring for 0.5-1.5 hrs, said extracting agent being one or more selected from the group consisting of alkyl dithiocarbonic acid and salts thereof, O,O′-dialkyl dithiophosphoric acid and salts thereof, and dialkylamino dithioformic acid and salts and said apolar organic solution being one selected from the group consisting of benzene, toluene and straight or branched alkanes having 6-12 carbon atoms, wherein the alkyl having 6-20 carbon atoms; and c) post-treating the reaction product to obtain copper nanoparticles.
摘要:
Disclosed are compounds of formula (I): wherein R1 and R2 are defined herein, which are useful as inhibitors of the kinase activity of the IκB kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.
摘要:
Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
摘要:
Disclosed are novel succinate derivative compounds of the formula(I)/(Ia): wherein R1, R2, R3, R4, R5, R6, R7, X and A are defined herein. The compounds are useful as inhibitors of cysteine proteases. Also disclosed are methods of using and methods of making such compounds.